The severe acute respiratory syndrome-associated coronavirus (SARS-CoV) recently emerged as the causal agent of an endemic atypical pneumonia, infecting thousands of people worldwide. We describe here a rapid and safe high-throughput assay for specifically screening for inhibitors of viral entry, using lentiviral pseudovirions whose entry is driven by SARS-CoV Spike glycoprotein. In preliminary studies, we found that many initial hits identified as potential inhibitors of entry mediated by SARS-CoV Spike, were also able to inhibit other pH-dependent viruses, likely due to gross effects on cellular function. In order to overcome this obstacle, in the same well, a second, unrelated pH-dependent viral envelope in conjunction with a lentiviral vector encoding a different reporter gene is utilized in order to reduce the numbers of false positive hits. Both targeted and general small molecule libraries were screened for inhibitors of SARS-CoV entry, and a number of compounds were identified that inhibit SARS-CoV entry and replication. In particular, we took advantage of our previous findings that cathepsin L in target cells is required for activation of SARS-CoV Spike, in order to focus on libraries of cysteine protease inhibitors. 16 positive "hits" with 95% inhibition or higher in the primary screen were further studied for drug dose--response, cell toxicity, and the ability to inhibit coronavirus 229E, Ebola and live SARS-CoV. Three related compounds, exhibiting potent antiviral activity (IC~50~  \< 10^−4^  μM) were selected for small animal studies.
